Skip to content

Incentive-based and Media Literacy Informed Approaches to Improve Vaping Cessation

Pilot Study of Incentive-based and Media Literacy-informed Approaches to Improve Vaping Cessation Among Young Adults

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05586308
Enrollment
40
Registered
2022-10-19
Start date
2023-12-07
Completion date
2025-06-30
Last updated
2026-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Behavior, Health Risk, Cessation, Smoking, E Cigarette Use, Engagement, Patient, Implementation Science, Incentives, Media Literacy, Peer Support

Brief summary

This study aims to evaluate the feasibility and compare the preliminary effect of vaping cessation program consisting of media literacy education and real-time text messaging support and leverage insights from behavioral economics to enhance social and financial incentives to improve program engagement, and eventually abstinence. Our hypotheses are that 1) the Combined arm is associated with improved vaping abstinence to the Media literacy and Financial incentive arms; and 2) the financial incentive-related arms (either Combined or Financial incentive) enhance engagement compared to the non-incentive related arms.

Detailed description

The objective of this pilot study is to evaluate the feasibility and compare the potential effect of different vaping cessation intervention components in addition to evidence-based text-messaging support, including 1) media literacy interactive e-learning lessons, 2) financial incentives, and 3) combined (media literacy + financial incentive) on vaping abstinence among current young adult vapers over a three-month timeframe with the following specific aims: Aim 1. To assess the feasibility of a multi-component vaping cessation program; and Aim 2 To evaluate the preliminary effect of a multicomponent vaping cessation program. Eligible participants are young adults aged 19-29 and are current vapers (i.e., has vaped in the previous 30 days).We will employ a 4-arm, feasibility randomized trial design to determine the preliminary effect of different vaping intervention components on vaping abstinence over a 3-month timeframe, consisting of a 1-month quitting preparation phase and 2-month abstinence phase. Eligible participants (n=80) will be randomized (in a 1:1:1:1 ratio), using a computer-generated algorithm, to to one of four vaping cessation interventions: 1) Active control: text-messaging support, 2) Media literacy: media literacy + text-messaging support, 3) Financial incentive: financial incentive + text-messaging support, and 4) Combined: media literacy e-learning lessons + financial incentive + text-messaging support, at the baseline visit. Regardless of intervention arms, all enrolled participants will receive receive an evidence-base text-messaging support program for quitting vaping (This is Quitting). Participants will be followed through a 3-month study period including a 1-month quitting preparation phase and a 2-month abstinence phase. All participants will be asked to provide the 5 saliva cotinine samples- at baseline and end-of-study visits and 3 at video calls (remote submissions). Participants who assigned to the financial incentive Combined groups will be provided monetary rewards for submitting saliva cotinine samples during the abstinence period. To examine the feasibility of biomarker testing for toxic exposures, for a subsample of 20 participants, a panel of biomarkers of toxic exposures will be measured at baseline and at the end of study.

Interventions

BEHAVIORALText-massaging suport

Text-messaging quitting support program (i.e., This is Quitting) is an evidence-based, free mobile program from Truth Initiative designed to help young people quit vaping. The program is fully automated and interactive. To establish or reinforce perceived social norms and social support around quitting, a majority of messages come from other users who have submitted them to the program.

BEHAVIORALFinancial incentive

1. Participants will earn $3 for each saliva cotinine sample submission regardless of positive or negative results after the quit day (an assessments at Week 6, Week 8, Week 10, and Week 12, during the abstinence phase) 2. Participants will earn additional escalating rewards for each negative sample- $7 for Week 6, $12 for Week 8, $17 for Week 10, and $22 for Week 12 (2 months after the target quit date). The bonus starts at $7 and increase by $5 for each subsequent negative cotinine sample (i.e., $7, $12, $17, and $22). 3. A reset contingency will be used. That is the reward amount will be returned back to original $7 if there is a missing or positive saliva cotinine sample

BEHAVIORALMedia literacy

Media literacy e-learning lessons cover topics regarding what e-cigarettes are and how they work, how nicotine and nicotine addiction affects the brain and behavior, how to prepare to quit vaping, developing a quit plan and how to deal with cravings and relapse. The program focuses on changing knowledge, attitudes and beliefs related to e-cigarette use, as well as emphasizing vaping related media literacy.

Sponsors

University of Nebraska
Lead SponsorOTHER
National Institute of General Medical Sciences (NIGMS)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Intervention model description

This study employs a pilot, 4-arm randomized clinical trial design.

Eligibility

Sex/Gender
ALL
Age
19 Years to 29 Years
Healthy volunteers
No

Inclusion criteria

* Aged 19-29 * Report vaping in the previous 30 days * Have access to internet/video chat/SMS text message * Are interested in quitting vaping in the next 30 days

Exclusion criteria

* Must meet all the inclusion criteria * Self-report as currently pregnant or planning to become pregnant in the next 3 months * Already involved in vaping cession programs (either behavioral or medical intervention)

Design outcomes

Primary

MeasureTime frameDescription
Engagement_remote checkin_33 monthsEngagement will be assessed by proportions of participants who submitted the remote saliva cotinine sample at remote checkin 3.
Retention3 monthsThe number of participants who completed the end-of-study assessment (Week 12).

Secondary

MeasureTime frameDescription
Biochemically Verified Vaping Abstinence3 monthsBiochemically verified vaping abstinence (negative results- \< 30 ng/mL) will be measured by saliva cotinine samples at end of study (Week 12).
Self-reported Vaping Abstinence3 monthsSelf-reported vaping abstinence will be assessed by the question "In the past 30 days, did you vape at all, even a puff of someone else?" at the end-of-study visit.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORTzeyu Michaud, PhD

University of Nebraska

Participant flow

Recruitment details

We worked with READi Core at the University of Nebraska Medical Center to first generate a list of potentially eligible participants, filtering for age and using smart text data to determine the vaping or smoking status. A study invitation email was sent to individuals on this potential participant list . In this email, interested individuals will be directed to complete web-based screening questions via REDCap to assess their eligibility.

Baseline characteristics

Characteristic
Age, Continuous23.5 years
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
9 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race/Ethnicity, Customized
Black
6 Participants
Race/Ethnicity, Customized
Other (e.g/., Asian or American Indian/Alaskan Native)
0 Participants
Race/Ethnicity, Customized
Unknown
3 Participants
Race/Ethnicity, Customized
White
31 Participants
Region of Enrollment
United States
11 participants
Sex/Gender, Customized
Female
7 Participants
Sex/Gender, Customized
Male
1 Participants
Sex/Gender, Customized
Non-binary
1 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 00 / 00 / 00 / 0
other
Total, other adverse events
0 / 00 / 00 / 00 / 0
serious
Total, serious adverse events
0 / 00 / 00 / 00 / 0

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026